CDT Equity Inc.

Analysis for Ticker: CDT

CDT Equity Inc describes itself as a data-oriented biopharmaceutical developer that uses artificial intelligence to find and reposition drugs without paying for the massive costs of late-stage clinical trials. In reality, the company operates as a closed loop designed to consume capital from the public rather than generate revenue from science. The math is a disaster because the box produces almost no income, generating less than 1,0$ million in revenue over five years while burning through 15,6$ million in operating cash during 2025. It is like a child who asks for a massive allowance to build a lemonade stand but spends every cent on fancy signs and first-class travel before ever buying a single lemon. With a total deficit of 68,3$ million and no remaining products to sell, the internal arithmetic is a terminal sequence of wealth destruction.